These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

529 related items for PubMed ID: 11180038

  • 1. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
    Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, Gerbeau C, Cambon N, Boger R, Rordorf C, Everolimus Phase 2 Study Group.
    Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
    [Abstract] [Full Text] [Related]

  • 2. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J, RADW 102 Renal Transplant Study Group.
    Nephrol Dial Transplant; 2004 Oct; 19(10):2606-14. PubMed ID: 15316094
    [Abstract] [Full Text] [Related]

  • 3. Everolimus in pediatric de nova renal transplant patients.
    Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H, Everolimus Pediatric Study Group.
    Transplantation; 2003 Jun 27; 75(12):2082-5. PubMed ID: 12829916
    [Abstract] [Full Text] [Related]

  • 4. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients.
    Budde K, Lehne G, Winkler M, Renders L, Lison A, Fritsche L, Soulillou JP, Fauchald P, Neumayer HH, Dantal J, RADW 102 Renal Transplant Study Group.
    J Clin Pharmacol; 2005 Jul 27; 45(7):781-91. PubMed ID: 15951468
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
    Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH, RADW 102 Renal Transplant Study Group.
    Eur J Med Res; 2005 Apr 20; 10(4):169-74. PubMed ID: 15946913
    [Abstract] [Full Text] [Related]

  • 6. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM, Snell GI, Valentine V, Aris R, Chan CK, Schmidli H, Pirron U.
    J Heart Lung Transplant; 2006 Apr 20; 25(4):440-6. PubMed ID: 16563975
    [Abstract] [Full Text] [Related]

  • 7. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 20; 38(7):2032-4. PubMed ID: 16979990
    [Abstract] [Full Text] [Related]

  • 8. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
    Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P, Samuel D, Nashan B, Klempnauer J, Langnas A, Calmus Y, Rogiers X, Abecassis M, Freeman R, Sloof M, Roberts J, Fischer L.
    Liver Transpl; 2006 Nov 20; 12(11):1640-8. PubMed ID: 16598777
    [Abstract] [Full Text] [Related]

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 20; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 10. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan 20; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 11. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.
    Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD.
    Clin Pharmacol Ther; 1998 Jan 20; 63(1):48-53. PubMed ID: 9465841
    [Abstract] [Full Text] [Related]

  • 12. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
    Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, O'Grady P, Krekler M, Mangold B, Christians U.
    Clin Pharmacol Ther; 1997 Sep 20; 62(3):311-21. PubMed ID: 9333107
    [Abstract] [Full Text] [Related]

  • 13. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT, Danguilan RA, Cabanayan-Casasola CB, Talusan-Tomacruz Y, Ona ET.
    Transplant Proc; 2008 Sep 20; 40(7):2211-3. PubMed ID: 18790195
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, Yacoub MH.
    Transpl Int; 2002 Dec 20; 15(12):649-54. PubMed ID: 12478413
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA.
    Transplant Proc; 2012 Jan 20; 44(1):154-60. PubMed ID: 22310603
    [Abstract] [Full Text] [Related]

  • 17. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul 20; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
    Wang CH, Chou NK, Wu FL, Ko WJ, Tsao CI, Chi NH, Hsu RB, Wang SS.
    Transplant Proc; 2006 Sep 20; 38(7):2132-4. PubMed ID: 16980022
    [Abstract] [Full Text] [Related]

  • 19. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun 20; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2009 Oct 20; 23(5):625-31. PubMed ID: 19656203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.